Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by LPL Financial LLC

LPL Financial LLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 38,382 shares of the biopharmaceutical company’s stock after acquiring an additional 8,114 shares during the period. LPL Financial LLC’s holdings in Halozyme Therapeutics were worth $1,384,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in HALO. ArrowMark Colorado Holdings LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth $44,170,000. Norges Bank purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $53,957,000. Macquarie Group Ltd. grew its holdings in shares of Halozyme Therapeutics by 22.8% during the first quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock worth $122,226,000 after buying an additional 595,220 shares in the last quarter. Mizuho Markets Cayman LP purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth $13,717,000. Finally, UBS Asset Management Americas Inc. grew its holdings in shares of Halozyme Therapeutics by 194.0% during the third quarter. UBS Asset Management Americas Inc. now owns 519,951 shares of the biopharmaceutical company’s stock worth $20,559,000 after buying an additional 343,087 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HALO. Benchmark reaffirmed a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a report on Friday, October 20th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $46.00 to $48.00 in a report on Wednesday, August 9th. HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $60.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, October 19th. StockNews.com lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, TheStreet raised shares of Halozyme Therapeutics from a “c+” rating to a “b” rating in a report on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $52.73.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $36.52, for a total transaction of $365,200.00. Following the sale, the senior vice president now owns 151,911 shares of the company’s stock, valued at $5,547,789.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 60,000 shares of company stock valued at $2,456,600 over the last 90 days. 2.30% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Down 2.4 %

Shares of HALO stock opened at $39.34 on Thursday. The company has a debt-to-equity ratio of 6.01, a current ratio of 7.63 and a quick ratio of 6.51. The firm has a market cap of $5.20 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 0.52 and a beta of 1.25. The company has a 50-day moving average of $37.32 and a two-hundred day moving average of $37.53. Halozyme Therapeutics, Inc. has a 1-year low of $29.85 and a 1-year high of $59.46.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.